The two new heterometallic Ru(II)-tpy/ferrocene
complexes [Ru(tpy)Cl2(mtefc)] (1) and [Ru(tpy)Cl2(mtpfc)] (2) (where tpy = 2,2′:6′,2′′-terpyridine,
mtefc = (2-(methylthio)ethyl)ferrocene, and mtpfc = (3-(methylthio)propyl)ferrocene)
have been synthesized and then characterized through elemental analysis,
followed by various spectroscopic (IR, UV–vis, 1D and 2D NMR)
and mass spectrometric techniques (MALDI TOF and ESI Q-TOF MS). UV–vis
and fluorescence spectroscopy and viscometry were employed to study
the interactions of the complexes 1 and 2 with calf thymus DNA. Both 1 and 2 expelled
ethidium bromide (EB) from the EB/DNA complex (K
sv = (1.5–1.8) × 104 M–1), which suggested that the complexes intercalated into the double
helix of DNA. Both complexes strongly quenched the fluorescence of
tryptophan residues in serum albumin through both static and dynamic
quenching. Molecular docking confirmed the intercalative mode of complex
interaction with DNA. The docking results implied that 1 and 2 interacted with hydrophobic residues of albumin,
particularly with those lying in the proximity of Tyr 160. We here
demonstrate the high cytotoxic potential of complexes 1 and 2 against the breast cancer cells that originated
either from humans (MDA-MB-231) or from mice (4T1), with apoptosis
being the main mechanism of complex-induced cell death. It is worth
noting that both complexes promoted activation of innate and acquired
antitumor immunity, which contributed to the reduced growth and progression
of mammary carcinoma in vivo.